Over $1.3 billion acquisition proceeds! Merck's small molecule cancer drug starts Phase 3 clinical trials in China
I'm PortAI, I can summarize articles.
Merck has launched a new drug, MK-3543 (bomedemstat), for the treatment of primary thrombocytosis, which has initiated Phase 3 clinical trials in China. Merck acquired Imago BioSciences for $1.35 billion in 2022, gaining access to this candidate drug. This oral medication is an LSD1 inhibitor that has shown anti-tumor effects in preclinical studies. Merck is conducting crucial Phase 3 randomized clinical trials to evaluate its efficacy in patients with primary thrombocytosis. The research initiated in China will assess the drug's efficacy and safety
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments